SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
Executive Summary
SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.
You may also be interested in...
GSK Ariflo Long-Term Efficacy Trials Needed For COPD Approval – FDA Cmte.
GlaxoSmithKline's Ariflo needs long-term efficacy studies to confirm the PDE-4 inhibitor's maintenance of effect in chronic obstructive pulmonary disease, an FDA advisory committee agreed Sept. 5
GSK Ariflo Long-Term Efficacy Trials Needed For COPD Approval – FDA Cmte.
GlaxoSmithKline's Ariflo needs long-term efficacy studies to confirm the PDE-4 inhibitor's maintenance of effect in chronic obstructive pulmonary disease, an FDA advisory committee agreed Sept. 5
GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth
GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions